The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.
Europe's pharmaceutical majors managed to post decent financials for the second quarter of 2022 and did not seem overly concerned about the rise in rhetoric across the Atlantic concerning future US drug pricing rises. The tough macro-economic backdrop, with inflation on the rise and recessions looming across the continent, failed to have much of an impact either.
At Novartis AG, chief financial officer Harry Kirsch addressed growing concerns about the prospect of a global recession, noting...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
